KU Leuven
Overview
KU Leuven is a prominent Belgian university that actively invests in spin-off companies and innovative ventures, aiming to translate academic research into practical applications and foster economic growth. The university's investment activities are primarily managed through its dedicated technology transfer office, KU Leuven Research & Development (LRD), which supports researchers in commercializing their innovations by establishing spin-off companies. This initiative has led to the creation of over 180 spin-offs, covering a diverse range of sectors including technology, healthcare, and engineering. The university's investment strategy encompasses various stages of company development, from seed funding to growth capital, facilitated by partnerships with financial institutions such as the Gemma Frisius Fund (GFF). Established in 1997 as a joint venture between KU Leuven, KBC Private Equity, and BNP Paribas Fortis Private Equity, GFF has invested approximately €24.5 million in 37 spin-off companies, providing essential seed capital to nurture early-stage ventures. Additionally, KU Leuven's Centre for Drug Design and Discovery (CD3) focuses on the discovery of new and innovative small molecule drugs, offering financial support and expert guidance to spin-offs in the pharmaceutical sector. Through these initiatives, KU Leuven demonstrates a strong commitment to fostering innovation and entrepreneurship, contributing significantly to the Belgian economy and the global advancement of science and technology. The university's comprehensive support system for spin-offs, encompassing financial investment, mentorship, and access to a vast network of academic and industry experts, positions it as a key player in translating research excellence into real-world solutions.
Investment Focus
- Innovative technology or research with commercial potential
- Strong management team
- Scalable business model
- Alignment with KU Leuven's strategic interests
Portfolio Companies
Get the full list of 54,000+ investors
KU Leuven and every other firm and angel in the database — as one spreadsheet you keep.
$19one-time payment · no subscription- All 54,000+ investors — VC firms, private equity, family offices and angels
- The key person to contact at each one, with their job title
- Their work email address
- Their phone number
- Their LinkedIn profile
- Delivered as a single .xlsx file — download it as many times as you like
Every profile on this site is one row of the file, with the contact details masked — browse a few before you buy.
Frequently asked questions about KU Leuven
What sectors does KU Leuven invest in?
KU Leuven invests in Financial Services, Technology, Healthcare, Energy, Consumer Goods and Real Estate, and is based in Belgium. KU Leuven is listed as a institutional investor in the ConnectSafely investor database.
What stage does KU Leuven invest at?
KU Leuven backs companies at Seed, Early Stage and Growth, writing cheques of 1M - 50M.
Which regions does KU Leuven invest in?
KU Leuven invests across United States, United Kingdom, Germany, France, Italy and Denmark.
Who are the partners at KU Leuven?
Team members listed for KU Leuven include José Ignacio Patiño Galdós (M&S CRM and Digital Director) and Jos van Pelt (Faculty Director).
What companies has KU Leuven invested in?
KU Leuven's portfolio includes Belfort, AstriVax, Optiflux, Tusk IC, Montis Biosciences, Flamingo Therapeutics, Oncurious and AnSem.
How do I contact KU Leuven?
KU Leuven's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
